Literature DB >> 19650670

Molecular and contextual markers of hepatitis C virus and drug abuse.

Paul Shapshak1, Charurut Somboonwit, Lydia N Drumright, Simon D W Frost, Deborah Commins, Timothy L Tellinghuisen, William K Scott, Robert Duncan, Clyde McCoy, J Bryan Page, Brian Giunta, Francisco Fernandez, Elyse Singer, Andrew Levine, Alireza Minagar, Oluwadayo Oluwadara, Taiwo Kotila, Francesco Chiappelli, John T Sinnott.   

Abstract

The spread of hepatitis C virus (HCV) infection involves a complex interplay of social risks, and molecular factors of both virus and host. Injection drug abuse is the most powerful risk factor for HCV infection, followed by sexual transmission and additional non-injection drug abuse factors such as co-infection with other viruses and barriers to treatment. It is clearly important to understand the wider context in which the factors related to HCV infection occur. This understanding is required for a comprehensive approach leading to the successful prevention, diagnosis, and treatment of HCV. An additional consideration is that current treatments and advanced molecular methods are generally unavailable to socially disadvantaged patients. Thus, the recognition of behavioral/social, viral, and host factors as components of an integrated approach to HCV is important to help this vulnerable group. Equally important, this approach is key to the development of personalized patient treatment - a significant goal in global healthcare. In this review, we discuss recent findings concerning the impact of drug abuse, epidemiology, social behavior, virology, immunopathology, and genetics on HCV infection and the course of disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19650670      PMCID: PMC4447498          DOI: 10.2165/01250444-200913030-00002

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  347 in total

1.  Drug-scene roles and HIV risk among Puerto Rican injection drug users in East Harlem, New York and Bayamón, Puerto Rico.

Authors:  Samuel R Friedman; Sung-Yeon Kang; Sherry Deren; Rafaela Robles; Hector M Colón; Jonny Andia; Denise Oliver-Velez; Ann Finlinson
Journal:  J Psychoactive Drugs       Date:  2002 Oct-Dec

2.  Sharing of drug preparation equipment as a risk factor for hepatitis C.

Authors:  H Hagan; H Thiede; N S Weiss; S G Hopkins; J S Duchin; E R Alexander
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

3.  Genotype distribution amongst hepatitis C patients in The Netherlands.

Authors:  M J de Vries; B te Rijdt; C M J van Nieuwkerk
Journal:  Neth J Med       Date:  2006-04       Impact factor: 1.422

4.  A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection.

Authors: 
Journal:  J Infect Dis       Date:  2005-10-28       Impact factor: 5.226

5.  HIV-1 superinfection is not a common event.

Authors:  Ricardo Sobhie Diaz; Regina Pardini; Márcia Catroxo; Eva A Operskalski; James W Mosley; Michael P Busch
Journal:  J Clin Virol       Date:  2005-08       Impact factor: 3.168

6.  Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications.

Authors:  D R Gretch; C dela Rosa; R L Carithers; R A Willson; B Williams; L Corey
Journal:  Ann Intern Med       Date:  1995-09-01       Impact factor: 25.391

Review 7.  Cellular immunity and acute hepatitis C infection.

Authors:  K Fitzmaurice; P Klenerman
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

8.  Factors influencing a low rate of hepatitis C viral RNA clearance in heroin users from Southern China.

Authors:  Rebecca-J Garten; Sheng-Han Lai; Jin-Bing Zhang; Wei Liu; Jie Chen; Xiao-Fang Yu
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

9.  Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus.

Authors:  M Damen; H L Zaaijer; H T Cuypers; H Vrielink; C L van der Poel; H W Reesink; P N Lelie
Journal:  Transfusion       Date:  1995-09       Impact factor: 3.157

Review 10.  Chronic HCV-related autoimmunity: a consequence of viral persistence and lymphotropism.

Authors:  A Kessel; E Toubi
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

View more
  3 in total

1.  Inactivation and survival of hepatitis C virus on inanimate surfaces.

Authors:  Juliane Doerrbecker; Martina Friesland; Sandra Ciesek; Thomas J Erichsen; Pedro Mateu-Gelabert; Jörg Steinmann; Jochen Steinmann; Thomas Pietschmann; Eike Steinmann
Journal:  J Infect Dis       Date:  2011-10-19       Impact factor: 5.226

2.  Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment.

Authors:  Juliane Doerrbecker; Patrick Behrendt; Pedro Mateu-Gelabert; Sandra Ciesek; Nina Riebesehl; Corinne Wilhelm; Joerg Steinmann; Thomas Pietschmann; Eike Steinmann
Journal:  J Infect Dis       Date:  2012-11-05       Impact factor: 5.226

3.  Estimated prevalence of Hepatitis C Virus infection in Canada, 2011.

Authors:  M Trubnikov; P Yan; C Archibald
Journal:  Can Commun Dis Rep       Date:  2014-12-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.